How to Choose a CDMO for Peptide Manufacturing

The short answer: Choosing a peptide CDMO turns on three things: synthesis-route fit — solid-phase (SPPS) is fast and flexible for complex or early-stage peptides, while solution-phase (LPPS) or hybrid routes are usually cheaper and more scalable for a long, high-volume commercial peptide, and the right choice depends on your sequence and scale; purification and impurity control — preparative chromatography is the yield-, cost- and quality-determining step for peptides, so it deserves as much scrutiny as the synthesis; and, right now, capacity — GLP-1 demand has tightened peptide manufacturing capacity across the industry, so a credible slot has to be secured early. Confirm any modifications your molecule needs (cyclisation, lipidation, conjugation) and screen the site against its FDA compliance record as you would any API supplier.

Peptides sit between small molecules and biologics: made by chemical synthesis but far larger and more complex than a typical small-molecule API, and increasingly in demand thanks to GLP-1 receptor agonists and a broad pipeline behind them. That demand has made peptide capacity one of the tightest constraints in sourcing, and it has raised the stakes on getting the synthesis and purification strategy right.

1. Match the synthesis route to your peptide and scale

The first and most consequential decision is how the peptide is made:

Solid-phase peptide synthesis (SPPS) — the peptide is built on a resin, one amino acid at a time. It is fast, flexible and well-suited to complex sequences and clinical-stage material, but it is reagent- and solvent-intensive, which affects cost and sustainability at large scale.
Solution-phase (LPPS) and hybrid routes — fragments are made and coupled in solution. These are often more economical and scalable for a long, high-volume commercial peptide, at the cost of more development work.
Recombinant expression — for some peptides, a biological route is an alternative entirely.

A CDMO steeped in SPPS is not automatically your best partner for a commercial-scale, cost-sensitive peptide, and vice versa. Choose the route for your sequence length, complexity and projected volume — and prefer a partner that can advise on the route rather than default to the one it owns.

2. Scrutinise purification and impurity control

For peptides, purification is not a finishing step — it is where quality, yield and cost are largely decided:

Preparative reverse-phase HPLC capability at your scale is the core asset; peptide impurity profiles (deletion, insertion and epimerised sequences) are demanding, and separating them drives both yield and cost.
Analytical depth to characterise and control that impurity profile to the standard your filing requires.
Yield economics — small differences in purification yield move commercial cost of goods substantially for a high-volume peptide.

Under-weighting purification is the classic peptide-sourcing mistake: two CDMOs with identical synthesis capability can differ sharply on the cost and quality of the purified product.

3. Confirm the modifications your molecule needs

Many modern peptides are not simple linear sequences. Confirm the CDMO can perform:

Cyclisation, disulfide-bond formation, and other structural features your peptide requires,
Lipidation or fatty-acid conjugation — the modification behind several long-acting peptides — and
any PEGylation or conjugation steps in your target profile.

A partner that can synthesise the backbone but not perform the modification is only half a supplier.

4. Secure scarce capacity early

The GLP-1 wave has changed peptide sourcing from a buyer's market to a capacity-constrained one:

Credible peptide capacity is booked ahead — both synthesis and, critically, large-scale purification — so timeline and slot conversations must happen early.
A second source is harder to assume than it used to be, which makes the single-versus-dual-source decision more pressing for a commercial peptide.
Scale-up continuity matters: a route developed at one scale must transfer to commercial volumes without a costly redesign or an unplanned technology transfer.

5. Screen GMP and the compliance record

Peptide APIs are held to the same GMP and inspection standards as any drug substance. Verify current GMP status for the specific site and read its FDA Form 483, Warning Letter and recall history as a pattern — the supplier-qualification discipline applies unchanged.

Common pitfalls

Defaulting to the CDMO's preferred route rather than the one your sequence and volume need.
Under-scoping purification, the step that actually decides peptide cost and quality.
Missing a required modification — a linear-peptide house cannot make your lipidated one.
Assuming capacity is available in a market reshaped by GLP-1 demand.

Where this fits

Peptide sourcing blends API supplier qualification with CDMO selection — synthesis-route fit, purification, modifications and, above all, capacity, screened on the usual GMP and compliance axes. If you are deciding between development capability and pure manufacturing, start with CRO vs CDMO vs CMO.

PharmaTek links API and CDMO capabilities to each company's regulatory and FDA compliance record across a directory of 22,000+ pharmaceutical companies and manufacturers, so a peptide shortlist can be built for capability and screened for compliance at once.

Frequently asked questions

What is the most important factor when choosing a peptide CDMO? Matching the synthesis route to your peptide and scale. Solid-phase synthesis (SPPS) suits complex and clinical-stage peptides; solution-phase or hybrid routes are usually cheaper and more scalable for a long, high-volume commercial peptide. After route fit, scrutinise purification capability — the step that decides peptide yield, cost and quality — and secure capacity early, because GLP-1 demand has tightened the market.

What is the difference between solid-phase and solution-phase peptide synthesis? Solid-phase synthesis (SPPS) builds the peptide on a resin one amino acid at a time — fast and flexible for complex or early-stage peptides, but reagent- and solvent-intensive at scale. Solution-phase (LPPS) and hybrid routes couple fragments in solution and are often more economical and scalable for long, high-volume commercial peptides, at the cost of more development. The best choice depends on sequence length, complexity and volume.

Why does purification matter so much for peptides? Because for peptides purification largely determines quality, yield and cost. Peptide impurity profiles — deletion, insertion and epimerised sequences — are demanding to separate, and preparative reverse-phase HPLC at scale is the core capability. Small differences in purification yield move commercial cost of goods substantially, so purification deserves as much scrutiny as the synthesis itself.

Is peptide manufacturing capacity constrained right now? Yes. Demand for GLP-1 receptor agonists and the broader peptide pipeline has tightened both synthesis and large-scale purification capacity across the industry. Credible capacity is frequently booked ahead, so slot and timeline conversations must happen early, and assuming a ready second source is riskier than it used to be.

Can a peptide CDMO handle modifications like lipidation or cyclisation? Some can and some cannot — it must be confirmed explicitly. Many modern peptides require cyclisation, disulfide-bond formation, or lipidation/fatty-acid conjugation (the modification behind several long-acting peptides). A CDMO that can synthesise the backbone but not perform your specific modification is only a partial supplier, so verify the exact modifications in your target profile.

Sourcing a peptide manufacturing partner? Explore the supplier directory or book a demo to screen candidates against live GMP and FDA compliance data.